Search results

The Department of Health has agreed that the March Drug Tariff Part VIIIA reimbursement price for the following items will be:  Flecainide 50mg tablets £5.61 Pioglitazone 15mg tablets £24.00 and not as printed in the March edition of the Drug…

The Department of Health has agreed that the March Drug Tariff Part VIIIA reimbursement price for the following items will be: Bumetanide 1mg tablets £2.50 Desmopressin 10micrograms/dose nasal spray £25.02 Flecainide 100mg tablets £5.88 and…

The Department of Health has agreed that the March Drug Tariff Part VIIIA reimbursement price for Trazodone 50mg/5ml oral solution sugar free £140.00 and not as printed in the March edition of the Drug Tariff

The Department of Health has agreed that the March Drug Tariff Part VIIIA reimbursement price for Fludrocortisone 100mcg tablets £87.00 Trazodone 100mg capsules £28.14 and not as printed in the March edition of the Drug Tariff

April 2016 Establishment and Practice Payments The current levels of Establishment and Practice Payments, set out below, will be extended until the 30th June 2016. Establishment Payments  Number of items per month for 1 April 2015 to 31…

The Department of Health has agreed that the April Drug Tariff Part VIIIA reimbursement price for the following items will be: Bumetanide 1mg tablets £2.05 Celiprolol 400mg tablets £39.65 Cimetidine 400mg tablets £19.99 Flecainide 100mg…

The Department of Health has agreed that the April Drug Tariff Part VIIIA reimbursement price for the following item will be: Desmopressin 10micrograms/dose nasal spray £24.00 and not as printed in the April edition of the Drug Tariff.

The Department of Health has agreed that the April Drug Tariff Part VIIIA reimbursement price for the following items will be: Fludrocortisone 100microgram tablets £96.00 Nitrofurantoin 100mg tablets £12.50 Nitrofurantoin 50mg tablets £11.50…

The Department of Health has announced the Part VIIIB prices which will apply to prescriptions from 1st May 2016. Part VIIIB May 2016

These reports explore trends in prescribing to help indicate the factors for growth in volume and cost of prescribing in England.